SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14792

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

SARS-CoV-2

Applications

ELISA, Immunohistochemistry, Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 5H4C5

Format

BSA Free

Concentration

1 mg/ml

View all Spike Antibodies »

Product Summary

Immunogen

Antibody was raised against a peptide corresponding to 12 amino acids near the cleavage site of SARS-CoV-2 Delta variant Spike protein. The immunogen is located within 650-700 amino acids of SARS-CoV-2 Delta variant Spike protein.

Specificity

The antibody can only detect SARS-CoV-2 Delta Variant Spike S1 protein and does not cross-react with the spike protein of other variants.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images

ELISA: SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India - BSA Free [NBP3-14792]

ELISA: SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India - BSA Free [NBP3-14792]

ELISA: SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India [NBP3-14792] - SARS-Cov-2 Spike P681R (Delta Variant) Antibodies Specifically Detect Delta Variant Spike S1 Protein in an ELISA. Coating Antigen: SARS-CoV-2 spike S1 proteins WT, alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), mu variant (B.1.621), and omicron variant (B.1.1.529), 1 ug/mL, incubated at 4C overnight. Detection Antibodies: SARS-CoV-2 Spike P681R (Delta Variant) antibody, NBP3-14792, 1 ug/mL, incubated at RT for 1 hr. Secondary Antibodies: Goat anti-mouse HRP at 1:5,000, incubated at RT for 1 hr.
ELISA: SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India - BSA Free [NBP3-14792]

ELISA: SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India - BSA Free [NBP3-14792]

ELISA: SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India [NBP3-14792] - ELISA Validation of Delta Variant Spike S1 Antibodies with SARS-CoV-2 Delta Variant Spike S1 Protein. Coating Antigen: SARS-CoV-2 spike S1 proteins, WT, Alpha and Delta variants, 1 ug/mL, incubated at 4C overnight. Detection Antibodies: SARS-CoV-2 Spike P681R (Delta Variant) antibody, NBP3-14792, dilution: 0.3-1000 ng/mL, incubated at RT for 1 hr. Secondary Antibodies: Goat anti-mouse HRP at 1:5,000, incubated at RT for 1 hr. SARS-CoV-2 Spike P681R (Delta Variant) antibody specifically detects spike S1 protein of Delta variant, but not WT and Alpha variant.
ELISA: SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India - BSA Free [NBP3-14792]

ELISA: SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India - BSA Free [NBP3-14792]

ELISA: SARS-CoV-2 Spike Antibody (5H4C5) - Delta Variant, B.1.617.2, India [NBP3-14792] - ELISA Validation of Delta Variant Spike S1 Antibodies with Mutant and WT Peptide. Coating Antigen: SARS-CoV-2 spike S1 peptides: WT, Alpha variant, and Delta variant, 1 ug/mL, incubated at 4C overnight. Detection Antibodies: SARS-CoV-2 delta spike P681R antibody, NBP3-14792, dilution: 0.3-1000 ng/mL, incubated at RT for 1 hr. Secondary Antibodies: Goat anti-mouse HRP at 1:5,000, incubated at RT for 1 hr. SARS-CoV-2 Spike P681R (Delta Variant) antibody detects Delta variant spike S1 peptide (681R), but not WT peptide (681P) and Alpha variant spike S1 peptide (681H).

Applications

Application
Recommended Usage

Immunohistochemistry

20 ug/mL
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Affinity purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Store at -20C long term. Avoid freeze-thaw cycles.

Background: Spike

The SARS-CoV-2 Spike protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1,2). The spike protein is the largest of the structural proteins, which also include the membrane (M), envelope (E), and nucleocapsid (N) proteins (1,2). The SARS-CoV-2 spike protein is a 1273 amino acid (aa) heterotrimeric class I fusion protein with each monomer having a theoretical molecular weight of approximately 180 kDa (1). The club-shaped spike protein contains several functional regions and domains including the S1 globular head region which contains the N-terminal receptor-binding domain (RBD) and the S2 stem region that contains the C-terminal fusion domain, two heptad regions, a transmembrane domain, and a cytoplasmic tail (1,2). The viral spike protein is critical for attachment of the virus with the host cell, resulting in fusion and virus entry into the cell (1,2). More specifically, the RBD of the spike protein is responsible for binding to the cell surface receptor angiotensin converting enzyme 2 (ACE2) (1,2). This spike-ACE2 interaction results in a conformational change permitting furin cleavage between the S1 and S2 domains and then cleavage at S2' by TMPRRS2, or another protease, allowing membrane fusion (1,2).

Given the critical role of the spike protein RBD in the interaction with the ACE2 receptor and viral entry, a number of neutralizing antibodies against the RBD have been developed as potential therapeutics for treating COVID-19 (3). These antibodies bind the RBD domain on the S1 subunit inhibiting the interaction with ACE2 (3). However, more studies need to be done as neutralizing antibodies can result in antibody-dependent enhancement, in which the viral entry and replication within the host cell is increased (4). One potential way to combat antibody-dependent enhancement is the use of nanobodies (4). Furthermore, there are currently several vaccine strategies that are in clinical trials, or recently federally approved, that utilize the spike protein in different forms (e.g. full length, S1 RBD, RBD-Fc, N-terminal) for protecting against SARS-CoV-2 infection (4,5). These vaccine strategies include DNA vaccines, viral vector-based vaccines, RNA vaccines, and subunit vaccines (4,5).

References

1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658

2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.

3. Ho M. (2020). Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antibody Therapeutics. https://doi.org/10.1093/abt/tbaa009

4. Samrat, S. K., Tharappel, A. M., Li, Z., & Li, H. (2020). Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research. https://doi.org/10.1016/j.virusres.2020.198141

5. Sternberg, A., & Naujokat, C. (2020). Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sciences. https://doi.org/10.1016/j.lfs.2020.118056

Long Name

Spike Protein

Alternate Names

S Protein

Gene Symbol

S

Additional Spike Products

Product Documents

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.